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Abstract
Background: Cancer and other disorders are due to genomic lesions. SNP-microarrays are able to measure
simultaneously both genotype and copy number (CN) at several Single Nucleotide Polymorphisms (SNPs) along
the genome. CN is defined as the number of DNA copies, and the normal is two, since we have two copies of
each chromosome. The genotype of a SNP is the status given by the nucleotides (alleles) which are present on the
two copies of DNA. It is defined homozygous or heterozygous if the two alleles are the same or if they differ,
respectively. Loss of heterozygosity (LOH) is the loss of the heterozygous status due to genomic events.
Combining CN and LOH data, it is possible to better identify different types of genomic aberrations. For example, a
long sequence of homozygous SNPs might be caused by either the physical loss of one copy or a uniparental dis-
omy event (UPD), i.e. each SNP has two identical nucleotides both derived from only one parent. In this situation,
the knowledge of the CN can help in distinguishing between these two events.
Results: To better identify genomic aberrations, we propose a method (called gBPCR) which infers the type of
aberration occurred, taking into account all the possible influence in the microarray detection of the homozygosity
status of the SNPs, resulting from an altered CN level. Namely, we model the distributions of the detected
genotype, given a specific genomic alteration and we estimate the parameters involved on public reference
datasets. The estimation is performed similarly to the modified Bayesian Piecewise Constant Regression, but with
improved estimators for the detection of the breakpoints.
Using artificial and real data, we evaluate the quality of the estimation of gBPCR and we also show that it outper-
forms other well-known methods for LOH estimation.
Conclusions: We propose a method (gBPCR) for the estimation of both LOH and CN aberrations, improving their
estimation by integrating both types of data and accounting for their relationships. Moreover, gBPCR performed
very well in comparison with other methods for LOH estimation and the estimated CN lesions on real data have
been validated with another technique.
Background
Although most of the human genome is identical among
individuals, there are about 10 million single nucleotide
polymorphisms (SNPs) which distinguish us [1]. SNPs
are single base-pair loci where the nucleotides can
assume two possible values (called alleles)a m o n gt h e
four bases (thymine, adenine, cytosine, guanine). In gen-
eral, since we have two copies of each chromosome, the
genotype at any SNP can be: AA, BB or AB,w h e r e
A and B represent the two alleles. Moreover, a SNP can
be classified as homozygous (i.e., AA or BB)o r
heterozygous (i.e., AB), whether or not its genotype
consists of two equal alleles. Cancer and several human
diseases are caused by genomic aberrations, which can
affect the homozygous status and/or the DNA copy
number (the normal copy number, CN, is two since we
have two copies of each chromosome, except for the
chromosomes X and Y). The former type of aberrations
is often displayed by unusual long stretches of homozy-
gous SNPs, called loss of heterozygosity (LOH) region.
The latter type of aberrations consists in genomic
regions with DNA copy number different from two.
In general, LOH can arise by several mechanisms, such
as deletions and germ-line or somatic recombinations.
When the LOH occurs without a change in copy number,
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of homozygosity, ROH). In the past, copy-neutral LOH
regions were usually explained as a consequence of an
uniparental disomy event (UPD), see [2]. Recently, long
homozygous segments have also been detected in gen-
omes of normal individuals, supporting the hypothesis
that some copy-neutral LOH segments might represent
autozygosity (see, for example, [3-5]). In the literature, it
has been shown a relationship between some tumors and
both types of aberrant events (see, for example, [6-8]).
Uniparental disomy (UPD) occurs when both homolo-
gues of a part of a chromosome are inherited from only
one parent. It can be divided in: uniparental isodisomy
(when the two copies are two replicates of one homolo-
gue of one parent) and the uniparental heterodisomy
(when both homologues are inherited from the same
parent). Because of meiotic recombination, a mixture of
both events is also possible, and similar events can also
happen during the mitosis. Moreover, in cancer cells,
the uniparental isodisomy can also occur when a homo-
logue of a part of a chromosome is lost and the remain-
ing homologue is duplicated. The autozygosity describes
a situation where the homologues are identical by des-
cendent (IBD), because they are inherited from a com-
mon ancestor. Inbreeding is usually uncommon because
of laws and social conventions, but it does occur in
small isolated populations.
SNP microarrays are able to measure simultaneously
both the DNA copy number and the genotype at each
SNP position considered [9]. We call LOH data the
homozygous status of the SNPs deduced from the geno-
typing data. By integrating the information given by
both LOH and copy number data, we can better identify
several types of lesions of the genome (regarding combi-
nations of both DNA copy number and LOH aberra-
tions). For example, when one copy of a chromosomal
segment is deleted, we usually detect a long stretch of
homozygous SNPs (since the genotype calling algorithm
is unable to distinguish between the presence of only
one copy and the presence of two equal copies), but the
same homozygous status can also occur for other rea-
sons, such as uniparental disomy. In this situation, the
knowledge of both types of data can lead to the correct
interpretation of the phenomenon, while with only one
type of data it would not be possible. Another example
is when an amplified genomic segment is present: if one
of the two copies of the segment is highly amplified,
then even the heterozygous SNPs will be likely detected
as homozygous, because the DNA quantity of one allele
is much higher than the other one. In this case again,
the integration of both types of data is able to better
identify the dosage of the DNA aberration.
Many methods have been developed for the estimation
of the copy number profile (see, for example, [10-14])
and others for the discovery of LOH regions from the
genotyping data, without distinguishing if they are
caused by either the loss of one copy or other genomic
events like uniparental disomy or autozygosity (see, for
example, [15,16]). To the best of our knowledge, only
one method integrates these two types of data for the
estimation of both copy number aberrations and copy-
neutral LOH regions and it uses a hidden Markov
model (HMM) [17]. Other statistical procedures use the
information regarding both the total and the allelic copy
number to infer these kind of lesions (for example,
[18-24]) and some of these algorithms are available only
for the analysis of data coming from Illumina Beadar-
rays. Finally, in [25] the authors describe an HMM with
t h es a m ep u r p o s e ,w h i c he m p l o y st h ea l l e l i cc o p yn u m -
ber data from a tumor sample and the genotyping data
from the matched normal sample.
Here, we propose a method which estimates the copy
number changes and the copy-neutral LOH regions at
the same time, using both LOH and DNA copy number
data. The estimation procedure consists of a Bayesian
piecewise constant regression, thus we call our algo-
rithm genomic Bayesian Piecewise Constant Regression
(gBPCR). Our model is more general than [17], since
the latter cannot be applied to data, whose DNA sample
come from a mixture of cell populations (which is
usually the case for samples of patients affected by can-
cer). Moreover, the algorithm in [17] needs the specifi-
cation of some parameters by the user and is sensitive
to their values.
Our method was implemented in R and is freely avail-
able at http://www.idsia.ch/~paola/gBPCR/ or in Addi-
tional file 1. Furthermore, an R package will be soon
available.
Methods
Because of the complexity of the biological model, we
first describe a preliminary simplified model (called
Model 1), which only estimates the copy number events
exploiting the relationship between copy number and
LOH data. Therefore, it does not identify copy-neutral
LOH regions (called IBD/UPD regions), which are due
to events like uniparental disomy, and it does not distin-
guish the normal regions from the gained one (because
we suppose that the capability of detection of the homo-
zygous status is the same in these two types of regions).
In the subsequent subsections, we add to the model the
detection of copy-neutral LOH regions (Model 2) and of
gained ones (Model 3). Therefore, the explanation is
structured in the following way:
￿ Model 1: relationship between LOH and copy
number data to detect copy number changes (apart
from the gained regions);
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region detection (i.e. determination of copy-neutral
LOH regions);
￿ Model 3: addition to Model 2 of the gained region
detection.
Each of the three models is contained in the subse-
quent. The final model (Model 3) represents our algo-
rithm for the estimation of both copy number changes
and copy-neutral LOH regions and we call it genomic
Bayesian Piecewise Constant Regression (gBPCR).
Model 1: relationship between LOH and copy number
data
Although in nature the copy number is an integer, the
raw copy number values detected by the microarray are
usually continuous values, due to technical procedures.
Moreover, the samples often contain also a percentage
of normal cells.
It is common practice to treat copy number data in a
log2ratio scale (where the ratio is defined with respect
to a normal reference dataset) which makes the errors
approximately normally distributed. Then, the copy
number profile is estimated as a piecewise constant
function (i.e. the genome is divided in regions of con-
stant copy number), where the levels assume real values.
For the purpose of our model, we estimate this profile
by mBPCR, which is a Bayesian piecewise constant
regression procedure [14]. It has been shown in [14]
that this method outperformed well-known other meth-
ods on several datasets.
Commonly, in biomedical/cancer research, after esti-
mating the log2ratio profile, the copy number aberra-
tions are defined as those regions with values outside an
interval around zero (notice that, in the log2ratio scale,
zero represents CN = 2, i.e. a normal copy number).
Often, the interval is a statistical confidence interval
computed on the basis of the samples of the whole
dataset.
In Model 1, our aim is to classify better the copy
number changes, trying to reduce the number of false
positives, by exploiting the relationship between copy
number and LOH data.
Mathematical model of the biology mechanism
The aim of Model 1 is to obtain a better estimation of the
true underlying copy number events, using both the
information given by copy number and LOH data. In a
genomic region, a copy number event is defined as a par-
ticular class of copy number values. The definition of the
categories into which the copy number values are divided
will follow from the description of the LOH data.
For the purpose of better identifying the copy num-
ber events, we can consider two classes of SNP
values: Heterozygosity (Het)a n dHomozygosity
(Hom). Thus, the LOH data are deduced from the
genotyping data, by mapping the genotypes AA and
BB into Hom and the genotype AB into Het, for all
SNPs. The genotype calling algorithm (e.g. BRLMM
[26]) is unable to distinguish between a homozygosity
due to the presence of two equal nucleotides or the
one due to the loss or high amplification of one of
them. Hence, the presence of heterozygosity can
ensure that the copy number is normal or gained
with a high probability, while the homozygosity can
b ed u et od i f f e r e n te v e n t s .I tf o l l o w st h a tt h e r ea r e
only four relevant classes of copy number events that
can be distinguished by looking at the LOH data.
Therefore, if we call Zi  the random variable which
represents a copy number event at SNP i,i tc a n
assume only the following values:
￿ Zi  = 2, when CN > 4 (amplification);
￿ Zi  = 0, when 1 < CN ≤ 4 (normal or gain);
￿ Zi  = -1, when CN = 1 (loss);
￿ Zi  = -2, when CN = 0 (homozygous deletion).
The homozygous deletion corresponds to the loss of
both copies of a genomic region. Ideally, the genotype
calling algorithm should detect a NoCall genotype at
the corresponding SNP position (i.e. it should not be
able to identify the genotype of the SNP). Although not
common, since cancer DNA samples usually contain a
mixture of normal and tumor cells (with also different
cancer cell subpopulations), the information given by
the NoCall genotype can be used to better distinguish
between a mono-allelic deletion and a bi-allelic (homo-
zygous) deletion.
Therefore, three different LOH variables are present
in the model: the true homozygous status in normal
cells (X
N), the homozygous status in abnormal cells
(X), which is the consequence of copy number changes
(in Model 1 we do not consider other biological
events), and the homozygous status detected by the
genotype calling algorithm (Y). The components of the
first two random vectors can assume only values in 
= {Het, Hom} and 
* ={ ∅, Het, Hom}, respectively,
and we suppose that they are independently distributed
as Bernoulli random variable. The components of Y
can assume values in  ={ NoCall, Het, NHet}( NHet
stands for “not heterozygous”, since the genotype call-
ing algorithm cannot distinguish between two equal
nucleotides, i.e. homozygosity, and the loss of one
copy).
A summary of the model can be found in Figure 1
and a summary of the notations is in Table 1. Ideally, at
each SNP i, the homozygous status in abnormal cells Xi
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in normal cells Xi
N and the occurred copy number
event Zi  , by the following relations:
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Nevertheless, the homozygous status of abnormal cells
estimated by the genotype calling algorithm (Yi)i s
affected by several sources of errors.
Hypothesis of the model
The genome of cancer cells can be divided in subregions
where the copy number is constant. Since we divided
the copy number values in four classes (i.e. the copy
number events), we can also consider regions with the
same copy number event.
Let us consider a genomic region where the micro-
array measures the DNA copy number and the geno-
type at n SNP loci. Then, from the previous
discussion, the vector of the copy number events at
all positions Z     = (,,) ZZ n 1 can be seen as a piece-
wise constant function. This function consists of k0
intervals with the same copy number event and with
boundaries 0 0
0
1
0
1
00
00 =< < < = − tt t t n kk ,,  so that
ZZ Z tt p pp   
− + == = 1
00 1 ,f o ra l lp = 1, ..., k0.T oe s t i -
mate this function we use a Bayesian piecewise con-
stant regression method, which determines the
number of segments k0, the boundaries (tt k 0
00
0 ,,  )
and the copy number events Z = (,, ) ZZ k 1 0  .
For any sample, we assume to have the homozygous
status detected by the genotype calling algorithm
(Y) and the profile of the log2ratio of the copy number
estimated by mBPCR. The estimated log2ratio profile
consists of ˆ k
cn intervals with boundaries
ˆ ˆ ,ˆ ,...,ˆˆ t
cn cn cn
k
cn tt t n cn == = () 0 01 and levels of the seg-
ments m  ∈
∧

k
cn
(mp  is the estimated log2ratio in the
p
th interval, for pk
cn =1, ,  ). This estimated profile is
used only to define the prior distribution of the ran-
dom vector Z (see Subsubsection “Z prior definition”),
while the LOH data Y are used to infer Z (the scheme
of the algorithm is in Figure 2). Notice that we do not
suppose to know X
N, i.e. the homozygous status in
normal cells. Moreover, we assume that, given the true
value of the homozygous status in normal cells X
N and
the copy number event Z at each position, the LOH
data points {} Yii
n
=1 are independent, since their values
depend only on both noise and genotype detection
errors.
Figure 1 Scheme of Model 1.T h ev e c t o rX of the homozygous
status of all SNPs in abnormal cells is completely determined, given
the vector X
N of their homozygous status in normal cells and the
vector Z  of their corresponding copy number events. Using this
relationship among X, X
N and Z  , we can estimate Z  , given the
observations Y
cn and Y (respectively, the raw log2ratio of the copy
number and the homozygous status in abnormal cells detected by
the genotype calling algorithm) and by specifying the prior
distribution of X
N. The observations Y
cn are used to defined the
prior distribution of Z  in the Bayesian model.
Table 1 Notations
Het heterozygous
Hom homozygous
NHet not heterozygous (is used when we cannot distinguish between
two equal nucleotides, i.e. homozygosity, and the loss of one
copy)
 {Het, Hom}

* {ø, Het, Hom}
 {Het, NHet, NoCall}
X
N true genotypes in normal cells ( Xi
N Î  )
X true genotypes in abnormal cells (Xi Î 
*)
Y genotypes detected by the genotype calling algorithm (Yi Î  )
Y
cn raw copy number data
Z  copy number events/aberrations
U  occurrence of copy-neutral LOH (i.e. IBD/UPD event)
W  IBD/UPD & copy number aberrations
({W i  = w}={Zz i  = , Ui  = u} for some w, z, u)
cn all copy number information (both raw data and estimated
profile by mBPCR)
p vector of posterior probabilities to be a breakpoint (for all SNP
positions)
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0,t h ep o s t e r i o r
distribution of Z  is
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and thus, if we condition only with respect to the
LOH data y, the posterior becomes
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where  and kn , are the domains of k and t,
respectively (they will be defined later).
To specify the model (see Figure 1), we need to define
the likelihood, i.e. the conditional distribution of Y, given
Z  and X
N. To model it, we take into account all the varia-
bility that can affect the genotype detection, such as: the
polymerase chain reaction (PCR) amplification, the pre-
sence of different cancer cell subpopulations or normal
cells, and the amplification of only one copy. For example,
the probabilities P( | , ) Y NHet X Het Z ii
N
i == =  0
and P( | , ) YH e t X H o m Z ii
N
i == =  0 are not zero,
because of the error in the genotype detection even in
case of a normal DNA sample. The probabilities
P( | , ) Y Het X Het Z ii
N
i == = −  2 and P( | , ) Y NHet X Hom Z ii
N
i == = −  2
are related to the detection errors due to the presence of
normal cells and/or different types of cancer cell
subpopulations, or to PCR amplification errors, while
P( | , ) Y NHet X Het Z ii
N
i == =  2 is related to the errors
that can be due to the amplification of only one
allele. Also P( | , ) Y Het X Het Z ii
N
i == = −  1 and
P( | , ) Y NHet X Het Z ii
N
i == = −  2 account for the errors
that can be due to the presence of cell subpopulations.
The set of conditional probabilities
{( | , ) , , , , , ,} P Yy X x Zz y x z ii
N
i == = ∈ ∈ = − −   21 0 2
are considered as parameters of the model. To quantify
them, we needed paired normal-cancer samples, since
they are related to the probability of detecting a certain
homozygous status in a cancer cell, given the corre-
sponding one in a normal cell of the same patient and
under some copy number event. Therefore, to compute
maximum likelihood estimates of these parameters, we
used 13 samples from an available cancer dataset con-
sisting of breast cancer cell lines [27,28] (see Section S.1
in Additional file 2, for further explanations).
To complete the Bayesian model, we need to define
the prior distributions of the other random variables.
For the parameters K and T, we consider distributions
similar to the ones used in mBPCR [14]:
PK k
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PK k
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Figure 2 Scheme of the algorithm corresponding to Model 1. The graph shows the algorithm for the inference of Model 1. The scheme of
gBPCR (i.e. Model 3) can be obtained by substituting p(z|k, t, y) with p(w|k, t, y) and by estimating w instead of z.
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0
1 k+ such that t0 =0 ,tk = n and tq Î {1,..., n -1 }f o r
all q = 1,..., k - 1, in an ordered way and without
repetitions.
The prior probabilities of heterozygosity of the SNPs
{( ) } P XH e t i
N
i
n = =1 are the frequencies of heterozygosity
computed on the samples of the matched race in the
HapMap project [3,29]. They are usually provided by
the manufacturer in the documentation related to the
microarray used. In Section “Results and Discussion”,
the microarray mostly employed is the GeneChip
Human Mapping 250K NspI (Affymetrix, Santa Clara,
CA, USA).
Z prior definition
The only prior that we have not yet defined is the one
of Z. While the estimated levels of the log2ratio profile
are continuous variables, Z classifies the copy number
as discrete events. Then, the major problem consists in
mapping the continuous values into the discrete values
of Z, i.e. in defining a partition of the log2ratio values
such that each interval corresponds to a particular copy
number event.
In the literature, most methods determine a confi-
dence interval around zero (which corresponds to CN =
2) and then consider all the log2ratio values above this
interval as gains and all values below as losses (see, for
example, [30,31]). This method is not suitable in our
case, since we want to classify also the events {CN =0 }
and {CN > 4}. Looking at the histogram of the estimated
log2ratio values (see, for example, in Figure 3 the histo-
gram derived from the 14 HIV lymphoma cell lines in
[32]), we can see that they have a multimodal density
with peaks corresponding to CN =1 ,CN = 2 and CN =
{3, 4}. Sometimes, we can even separate the peaks of
CN =3a n dCN = 4. Similarly to [33], we model this
density as a mixture of normal distributions (a way to
estimate this mixture density can be found in Section
S.2 in Additional file 2). Once the parameters of the
density are estimated, we can define a function to map
the log2ratio values into the copy number event values:
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where ˆ , ˆ  cn cn
2 () are, respectively, the estimated
mean and variance of the normal distribution corre-
sponding to CN = cn.
From the definition of fLOGtoZ, for all p = 1,..., ˆ kcn ,w e
define the prior distribution of Zp as:
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where cn represents all copy number information
(both raw data and estimated profile by mBPCR) and
Mp is the random variable representing the log2ratio
value in the p
th segment. From the mBPCR model,
given cn, Mp is normally distributed with mean ˆ mp and
variance ˆ Vp where ( ˆ mp , ˆ Vp ) are the posterior mean
and variance of Mp estimated by mBPCR, respectively.
The estimation
To estimate the piecewise constant profile of the copy
number events, we define the estimators of k0 (the num-
ber of segments) and t
0 (the boundaries) similarly to the
ones in the mBPCR method [14]:
Kp k c n
k
 01 =
∈
argmax ( | , ),

Y (2)
TY Y
t
 BinErrAk pq
p
kn
Tt c n k p k c n == ′
′∈ = ∧
argmax ( | , , ) ( | , ).
,
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
01 1
P
n n( , ) max ′ −
= =
−
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∧
tk
k
k
q
k q 1
2 1
1 01
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Namely, T  BinErrAk corresponds to the k
∧
01 positions
which have the highest posterior probability to be a
breakpoint. The main differences with respect to
mBPCR are in the prior over K and in the estimation of
K. Instead of using a uniform prior and an estimator
which minimizes the posterior expected squared error,
Figure 3 Example of a histogram of estimated log2ratio levels.
The graph shows the histogram of the mBPCR estimated log2ratio
levels of the profiles of 14 HIV lymphoma cell lines in [32].
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2 and an estima-
tor which minimizes the 0-1 error, in order to reduce
the false discovery rate (FDR) in case of few segments.
Another difference with respect to mBPCR consists in
the level estimation. While in the copy number model
the levels were continuous random variables, now they
assume categorical values. Hence, they are estimated
separately (as before) with the MAP estimator instead of
the posterior expected value,
ZZ z k c n p
z
p  ==
∈− −
∧ ∧
argmax ( | , , , ),
{,, , } 21 0 2
P Yt (4)
for p = 1,..., k
∧ ,w h e r e t
∧ and k
∧ are any estimate of t
0
and k0, respectively. For the computation of all the pos-
terior probabilities involved, we used dynamic program-
ming as described in Section S.3 in Additional file 2.
Let us define yij =( yi+1, ..., yj), representing the LOH
data points in the interval [i +1 ,j], and Kij as the ran-
dom variable which represents the number of segments
in the interval [i +1 ,j]. Using Bayes’ Theorem and the
independence of the LOH data points belonging to dif-
ferent segments, the probability in Equation (4), given
the LOH data y, can be written as,
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Therefore, if the boundary estimator misses a clear
boundary between t p
∧
−1 and t p
∧ , then the probability at
the denominator of Equation (5) could be zero and thus
the level would not be estimated. The best way to pre-
vent this event consists in using a good estimator for
the boundaries.
Previously, in [14] we found that the boundary estima-
tor T  BinErrAk is an estimator with a high sensitivity, but
medium FDR. The problem of this estimator is the fol-
lowing. The vector p of the posterior probabilities to be
a breakpoint at each point of the sample usually repre-
sents a multimodal function with maxima at the break-
point positions, but often in a neighborhood of each
maximum there are other points with high probability
because of the uncertainty (see Figure 4). Hence, if we
take the first k
∧
01 points with the highest probability
(according to the definition of T  BinErrAk ), we could take
points in the neighborhood of the higher maxima and
not some maxima with a lower probability (see Figure
4). As a consequence, if k0 was estimated with its exact
value then the sensitivity of the T  BinErrAk would be
lower. In this case, we could lose important breakpoints
so that the denominator in Equation (5) would become
zero. In practice, K  01 often slightly overestimates k0,
because of the high noise of the data, and thus this phe-
nomenon should not happen, but to prevent even this
rare case we searched for a way to improve the estima-
tion of the boundaries.
Since commonly the vector of the posterior probabil-
ities shows clearly the position of the breakpoints in
correspondence to the maxima, we estimate the number
of the segments and the breakpoints with the number of
peaks and the locations of their maxima, respectively
(see Section S.4 in Additional file 2). Essentially, the
algorithm for the determination of the peaks, after
applying a kernel method to reduce the noise of the
function, uses two thresholds: one for the determination
of the peaks (thr1)a n do n ef o rt h ed e f i n i t i o no ft h e
values close to zero (thr2). Therefore, we will denote
the corresponding estimators by K Peaks thr thr  ,, 12 and
T  Peaks thr thr ,, 12 .
In Section “Results and Discussion”,w ew i l lc o n s i d e r
several pairs of thresholds and we will apply the corre-
sponding estimators to simulated data, in order to deter-
mine the best paired thresholds and to compare their
performance with T  BinErrAk . We will also compare
T  BinErrAk with T  Joint , another boundary estimator
described in [14].
Model 2: addition of the IBD/UPD region detection
LOH data are used in biology not only to better identify
regions of loss and amplifications, but, especially, to
detect regions of copy-neutral LOH, which can be
Figure 4 Example of estimated posterior probabilities to be a
breakpoint. The graph shows, for each probe, the estimated
posterior probability to be a breakpoint on a sample of dataset B.
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Page 7 of 18identified by unusual long stretches of homozygous
SNPs, with normal copy number. In Section “Back-
ground”, we explained that this type of aberrations can
be a consequence of UPD (either uniparental isodisomy
or heterodisomy) or autozygosity (IBD regions). From
the description of these genomic events, it follows that
the uniparental isodisomy and the IBD regions can be
detected because they appear as a long sequence of
homozygous SNPs with a low probability to occur, while
the uniparental heterodisomy consists in a sequence of
both homozygous and heterozygous SNPs as in a nor-
mal condition. Therefore, without the genotypes of the
parents, from SNP data we can only detect the unipar-
ental isodisomy (iUPD) and the IBD segments. In the
following, we will consider only these two events, refer-
ring to them as IBD/UPD events.
Since an IBD/UPD event, by definition, only exists in
regions of normal copy number (CN = 2), the only
probabilities which are affected by the presence of this
event are those involving {Z = 0}. Therefore, we define
the following sets of conditional probabilities
{ ( | ,,) , , } P Yy X x Z U y x ii
N
i i == = = ∈ ∈   00  and
{( | , ) , } P Yy Z U y i i i === ∈   01  ,w h e r et h ev a r i a b l e
Ui  indicates if an IBD/UPD event occurred at SNP i (if
it happened Ui  =1 ,o t h e r w i s eUi  = 0). We can notice
that, given {Ui  =0 , Zi  = 0}, the distribution of Yi is
equal to the conditional distribution with respect to
{ Zi  = 0} in Model 1, since the latter was modeled with
no possibility of an IBD/UPD event. Instead, in case of
an IBD/UPD event, we do not need to condition with
respect to Xi
N , since, in case of a somatic iUPD event,
the genotype of an iUPD region is independent of the
homozygous status of the same region in a normal cell.
Otherwise, in case of autozygosity or germ line iUPD,
the genotypes of normal and abnormal cells are the
same and it makes no sense to condition one to the
other.
In the new framework, we define the vector of the
aberration events at n SNP loci as W     = (, ,) WW n 1 ;
here the aberrations regard both copy number changes
and IBD/UPD regions. Each component W i  of the vec-
tor assumes values: -3 ( Zi  =0a n dUi  =1 ,i . e .I B D /
UPD event), -2 ( Zi  = -2, i.e. homozygous deletion), -1
( Zi  = -1, i.e. loss), 0 ( Zi  =0a n dUi  =0 ,i . e .n o r m a l
state or gain), 2 ( Zi  = 2, i.e. high amplification); a gra-
phical representation of the model is given in Figure 5.
As previously, we can divide the genome in intervals
corresponding to the same aberration event, i.e the pro-
file of the aberrations consists of k0 intervals, with
boundaries 0 0
0
1
0
1
00
00 =<<< < = − tt t t n kk  ,s ot h a t
WW W tt p pp   
− + == = 1
00 1 : , for all p = 1, ..., k0.T h ee s t i -
mation procedure is similar to the one of Model 1. The
estimators of k0 and t
0 are the same and, given k
∧ and
t
∧ (any estimate of k0 and t
0, respectively), we estimate
the aberration events in each interval with their MAP
estimators,
WW w k c n p
w
p  ==
∈− − −
∧∧
argmax ( | , , , ),
{,,, , } 321 0 2
P Yt (6)
for p = 1,..., k
∧ . Notice that, for w = -2, -1, 2, the pos-
terior probability P(Wp = w|Y, t
∧ , k
∧ , cn) is equal to P
(Zp = w|Y, t
∧ , k
∧ , cn), while for w = -3, 0 we have,
P
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Figure 5 Scheme of Model 2 and 3. The vector W  of aberration
events represents the lesions derived from both IBD/UPD events
(U  ) and copy number event ( Z  ), at each SNP position. The
vector X of the homozygous status of all SNPs in abnormal cells is
completely determined, given the vector X
N of their homozygous
status in normal cells and the vector W  of their corresponding
aberration events. Using this relationship among X, X
N and W  ,w e
can estimate W  , given the observations Y
cn and Y (respectively,
the raw log2ratio of the copy number and the homozygous status
in abnormal cells detected by the genotype calling algorithm) and
by specifying the prior distributions of U  and X
N. The observations
Y
cn are used to defined the prior distribution of Z  in the Bayesian
model.
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Page 8 of 18a n dw ea s s u m et h a tP ( Up =1 )= :pupd,f o ra l lp = 1,...,
k
∧ .
Both {( | ) , } P Yy W y i i == − ∈  3  and pupd are para-
meters of the model. For the maximum likelihood esti-
mation of {( | ) , } P Yy W y i i == − ∈  3  , we used 11 IBD/
UPD regions previously found by us on 5 samples of
patients with hairy cell leukemia [34] and on the B-cell
lymphoma cell line KARPAS-422. All regions were
detected by dChip [16] and their width was between 3
Mb and 100 Mb (covering from 300 to 9800 SNPs), so
that they were large enough to be really considered
IBD/UPD regions (for further explanations, see Section
S.1 in Additional file 2).
Values for the parameter pupd
We expect the prior probability of an IBD/UPD event to
be low. In order to estimate the order of magnitude of
this parameter, we considered two studies on IBD
regions: [6] and [3]. In the former, they considered as
IBD regions only stretches of at least 50 homozygous
SNPs (with at maximum 2% of heterozygous) longer
than 4 Mb and the platform used was the Affymetrix
GeneChip Human Mapping 50K Array. In the latter, a
denser microarray was used and the stretches consid-
ered were longer than 1 Mb (with at least 50 probes) or
longer than 3 Mb. Using the data of the former paper
(only the normal samples), we estimated pupd ≈ 1.7·10
-3.
Instead, with the data of the latter, we estimated pupd ≈
1.5·10
-3 considering all regions greater than 1 Mb, while
pupd ≈ 1.46·10
-4, considering only the regions greater
than 3 Mb. The differences in the estimated values are
due to the different resolution of the technologies used
(in fact, in the former the number of SNPs used was
58,960, while in the latter it was 3,107,620). Moreover,
the probability depends on the minimum length allowed
for these regions. The wider the regions are, the higher
is the probability that the regions represent “abnormal-
ities” and the lower becomes the probability of their
occurrence (so that pupd is lower). Therefore, in the fol-
lowing applications (see Section “Results and Discus-
sion”), we will use two values: pupd =1 0
-3 and pupd =
10
-4.
Another possible way to solve the problem could be to
assign a prior distribution to pupd (for example, a uni-
form distribution over its range) and integrate it out in
the equations of the model.
Model 3: addition of the gained region detection
In the description of Model 1, we explained our
assumption that there is no difference in the genotype
detection between a normal or gained region. Therefore,
in Model 1 (and in Model 2), we defined a single class
for the normal or gained regions. But, for the biological
studies, it is relevant to distinguish these two copy num-
ber events and this distinction is based essentially on
the estimated copy number (since there is no difference
in the distribution of the detected genotypes, due to the
previous discussion). As a consequence, the probability
of Yi given a normal (i.e. { Zi  = 0}) or gained copy num-
ber (i.e. { Zi  =1 }={W i  = 1}) is the same,
P
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We also need to define two distinct prior probabilities
for the normal copy number and the gain event. Simi-
larly to its previous definition, for all pk
cn =1, ,  ,t h e
new prior of Zp is given by,
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In the following, Model 3 (which is the complete
model) will be called genomic Bayesian Piecewise
Constant Regression (gBPCR).
Adjustment of the parameters related to NoCall
The probabilities {P(Yi = NoCall| Xi
N = x, W i  = w), x
Î  , w = -3, -2, -1, 0, 2} are related to the detection of
NoCalls under some conditions. Generally, the presence
of NoCalls is not only due to diffculties of the genotype
calling algorithm in the detection of the genotype (tech-
nical noise) but also to the noise of the sample because
of differences in the quality of extracted DNA. There-
fore, we need to adjust the estimated values of these
parameters on the basis of the sample noise.
Since usually the NoCall rate (i.e. percentage of
NoCalls in the sample) increases with the noise of the
sample, we assume that, given { Xi
N = x, W i  = z}, the
probability of detecting a NoCall at SNP i in sample s is
proportional to a parameter px,z (which depends on the
technical noise) by a factor θs (which depends on the
sample noise),
P( | , , ) . , YN o C a l l X x Wz sp ii
N
i xz s == = ≈   (9)
If we condition over the values of Xi
N and estimate P
( Xi
N = Het) = 1/2 for a generic SNP i (by considering a
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Page 9 of 18uniform distribution over the four possible combinations
of alleles AA, AB, BA, BB), we can compute the NoCall
rate in regions with copy number event z in the follow-
ing way,
P
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Therefore, by applying Equations (9) and (11), for any
pair of samples (Sample 1 and 2), we can write the con-
ditional probability of NoCall, given { Xi
N = x, W i  = z},
in Sample 1 in terms of the corresponding probability in
Sample 2,
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In the following, we will denote the sample to esti-
mate with s = 1 and the reference sample with s =2 .
Using Equation (12), the values of the parameters
related to NoCall detection are adjusted for Sample 1,
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for z =- 2 ,- 1 ,0 ,2 ,w h e r er1(z)a n dr2(z)a r ea ne s t i -
mate of the NoCall rate in regions with copy number
event z, for Sample 1 and 2, respectively. By applying
Equation (10) with P( Xi
N = Het) = 1/2, r2(z) can be
computed from the estimated values of P(Yi =
NoCall| Xi
N = Het, W i  = z)a n dP ( Yi = NoCall| Xi
N =
Hom, W i  = z)
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for z = -2, -1, 0, 2. r1(z) is the frequency of NoCall in
regions with copy number event z of Sample 1, for z =
-2, -1, 0, 2.
The estimated value of the probability P(Yi =
NoCall|W i  = -3) is adjusted in a different way. On the
reference samples, we found, as expected, that
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that is, the NoCall rate in IBD/UPD regions is
approximately equal to the NoCall rate in normal
regions. Therefore,
P
∧
== − = = (| , ) ( ) . YN o C a l l W s r i i  31 0 1
In Section “Results and Discussion”,w ew i l lc o m p a r e
the estimations resulting from gBPCR with and without
the adjustment of these parameters.
Results and Discussion
In this section, we apply gBPCR to both artificial and
real data. First, we compare t h eb o u n d a r ye s t i m a t o r s
(described in the previous section) on data simulated by
using Model 1. Then, we evaluate the detection of IBD/
UPD regions on the artificial dataset of [35], in compari-
son with three well-known methods for LOH estima-
tion. Using the same data, we also show the difference
in the estimation when adjusting the parameters. Finally,
we show the performance of gBPCR, when applied to
real data.
With the current implementation, on a computer with
dual CPU (AMD Opteron 250, 2.4 GHz) and 4 GB
RAM, the algorithm needed almost two days to estimate
the profile of an Affymetrix GeneChip Mapping 250K
NspI sample (using kmax = 50). Nevertheless, the com-
putations can be performed by chromosome (and by
arm for the longest chromosomes), reducing the
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Page 10 of 18computational cost. In any case, an optimized version of
the code will be soon available.
Comparison of the breakpoint estimators on simulated
data
In Section “Methods”, we have described several possi-
ble boundary estimators: T  BinErrAk , T  Joint and
T  Peaks thr thr ,, 12 . The last one actually defines a class of
estimators which depend on the values of the thresholds
thr1 and thr2. We tried several pairs of the following
types of thresholds:
￿“ 005” := max(0.005, quantile of p at 0.95)
￿“ 01” := max(0.01, quantile of p at 0.95)
￿“ 01_90” := max(0.01, quantile of p at 0.90)
￿“ mad” := median(p)+3*mad(p)
where mad is the median absolute deviation and p is
the vector of posterior probabilities to be a breakpoint.
All these thresholds derive from different definitions of
which probability values are to be considered significant.
We assessed the quality of all the estimators of k0 and
t
0 considered, by applying them on two artificial datasets
(called datasets A and B), each of 100 samples. We used
as prior probabilities of heterozygosity the frequencies
of heterozygosity (in the CEU population of the Hap-
Map project [29]) given by the annotation file of the
Affymetrix GeneChip Mapping 250K NspI microarray.
Just for illustrative purpose and because of limited com-
putational time, we considered only the SNPs of a single
chromosome (chromosome 22), hence the number of
data points in each sample is n = 2520. Since our com-
plete model (Model 3) does not provide a realistic way
to simulate IBD/UPD regions and the identification of
gained regions depends mainly on copy number data,
the samples were generated using Model 1.
Simulation description
Since the Model 1 assumes to know the estimated copy
number profile given by mBPCR, for both datasets, we
fixed the estimated segment number ˆ k
cn =1 5 ,t h ee s t i -
mated boundaries ˆ t
cn = (0, 27, 31, 161, 273, 585, 633,
1006, 1050, 1054, 1309, 1607, 1754, 2100, 2432, 2520)
(generated uniformly random given ˆ k
cn = 15) and the
prior distribution of Z (see Supplementary Table S.1 in
Additional file 2, for dataset A,a n dT a b l e2 ,f o rd a t a s e t
B). The profiles of the samples in dataset A should be
estimated easily, since in each segment the prior distri-
bution of Z is quite peaked.
Given the previous parameters ( ˆ k
cn , ˆ t
cn and the Z
prior) and the estimated values of the other parameters
of the model, we used the following steps to generate
each LOH sample:
1. we generated a true profile of the homozygous
status in normal cells X
N,b yu s i n gt h ep r i o rp r o b -
abilities of heterozygosity, described previously;
2. we generated a true copy number event profile Z  ,
by using the prior distribution of Z (notice that in
some cases the final profile can have less than 15
segments, since, if consecutive segments have the
same copy number value, then they are joined
together);
3. given the true copy number event profile and the
profile of the homozygous status in normal cells, we
generated Y (the profile of the homozygous status in
cancer cells detected by the genotype calling algo-
rithm), by using the conditional probability distribu-
tions of Model 1.
Results of the comparisons
To evaluate the performance of the estimators, we com-
puted several error measures regarding the estimation of
the number of segments (0-1, absolute and squared
errors), the boundary estimation (binary error, sensitivity
and false discovery rate, FDR) and the profile estimation
(sum of squared distance, SSQ, sum 0-1 error, sensitivity
and FDR for all copy number events). The explanation
of these error measures can be found in Section S.5 in
Additional file 2.
By applying the pairs of estimators ( K  01, T  Joint ),
( K  01, T  BinErrAk ), and ( K Peaks Peaks   ,, ,, , 005 005 005 005 T )t o
dataset A, the latter two appeared the best performing
methods with respect to the error measures considered
(see for example Table 3).
Based upon these results, we decided to not apply the
estimators ( K  01, T  Joint ) on dataset B and to try other
paired thresholds for T  Peaks thr thr ,, 12 , in order to reduce
the FDR of the boundary estimation. By looking globally
at the results of all error measures (see Table 3, Supple-
mentary Tables S.2-S.5 and Supplementary Figures
S.2 and S.3 in Additional file 2), we can suggest
Table 2 Prior distribution of Z in the simulated dataset B.
segment
prior I II III IV V VI VII VIII IX X XI XII XIII XIV XV
P(
Zp
=2 ) 0 0.1 0 0.1 0.5 0.1 0 0 0.1 0.5 0 0.1 0.5 0.1 0
P(
Zp
=0 ) 0.1 0.6 0.1 0.6 0.4 0.6 0.1 0.1 0.6 0.4 0.1 0.6 0.4 0.6 0.1
P(
Zp
=- 1 ) 0.6 0.3 0.6 0.3 0.1 0.3 0.6 0.4 0.3 0.1 0.6 0.3 0.1 0.3 0.6
P(
Zp
=- 2 ) 0.3 0 0.3 0 0 0 0.3 0.5 0 0 0.3 0 0 0 0.3
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( K Peaks Peaks   ,, ,, , 01 01 01 01 T ), ( K Peaks mad Peaks mad   ,, ,, , 01 01 T )o r
( K Peaks mad Peaks mad   ,, ,, , 01 01 T ). Moreover, from the study of
the behavior of ( K Peaks mad Peaks mad   ,, ,, , 01 01 T )a n d
( K Peaks mad Peaks mad   ,, ,, , 01 01 T ), we can understand the role
of the two thresholds in our algorithm for the determi-
nation of the maxima in a multimodal function (see Sec-
tion S.4 in Additional file 2). The threshold thr1 is used
to decide which points belong to the same peak: all the
points, between two regions of points below thr1,a r e
considered in the same peak. Hence, with a low thresh-
old, more points are considered belonging to the same
peak and thus we can eliminate lot of false breakpoints
(like in ( K Peaks mad Peaks mad   ,, ,, , 01 01 T )). But, at the same
time, if two true peaks are close, then it is possible that
they are considered as only one peak, losing a true
breakpoint (low sensitivity). Instead, the threshold thr2
is used to choose which estimated breakpoints are sig-
nificant for the regression, i.e. if their posterior probabil-
ities are to be considered different from zero. Therefore,
using a lower value of thr2, we select a higher number
of breakpoints obtaining a higher percentage of both
false ones (high FDR) and true ones (high sensitivity, as
in ( K Peaks mad Peaks mad   ,, ,, , 01 01 T )).
A detailed description of the results obtained in the
comparison is in Section S.5 in Additional file 2.
Comparisons on simulated data with LOH regions
In order to evaluate the IBD/UPD detection of gBPCR,
we applied it to simulated data of [35]. These data are
based on three real samples of the HapMap dataset (see
[1]), obtained with the Affymetrix GeneChip Mapping
250K NspI. For each sample and signal to noise ratio
(SNR) value, the authors simulated two profiles: one
with regions of copy-neutral LOH and one with regions
of loss. In both cases the number of regions was 50 and
their width ranged from 20 SNPs to a whole chromo-
some. The values of SNR considered were 5, 2 and 1.25.
Therefore, the total number of samples was 18, because
for each normal sample we had two LOH profiles and
three SNR values. The authors simulated the noise and
the aberrations at probe level intensity saving the data
in .CEL file format, thus we used BRLMM [26] to
extract the genotyping data and CNAT 4.01 [36] for the
raw copy number data.
Similar to [35], the estimation of gBPCR was com-
pared with the ones given by three well-known methods
in the field: dChip [16], CNAT 4.01 [36] and PennCNV
[24]. The evaluation has been done by computing the
true positive rate (TPR) and the false positive rate
(FPR), i.e. the proportion of SNPs inside the LOH
regions that are correctly identified (as belonging to a
LOH region) and the proportion of SNPs outside these
segments that are wrongly identified (as belonging to
them), respectively. We used ( K Peaks Peaks   ,, ,, , 01 01 01 01 T ),
( K Peaks mad Peaks mad   ,, ,, , 01 01 T )o r( K Peaks mad Peaks mad   ,, ,, , 01 01 T )
as paired estimators of the number of segments and the
boundaries, and either pupd =1 0
-3 or pupd =1 0
-4 mas
the prior probability of IBD/UPD.
Since CNAT does not consider the NoCall SNPs
(called non-informative SNPs) for the estimation of the
LOH profile, we compared the TPR and FPR computed
using only either the informative or the non-informative
SNPs (see Supplementary Figures S.4, S.5, S.6 and S.7 in
Additional file 2).
Overall, all versions of gBPCR behaved similarly on
these data and they outperformed PennCNV, CNAT
and dChip. Moreover, dChip failed to give a good esti-
mation in presence of high noise, while PennCNV did
not detect almost any LOH aberration. Four examples
of profile estimation in samples with SNR = 1.25 (high
noise) are shown in Figure 6 (their corresponding LOH
Table 3 Comparison among the breakpoint estimators with respect to error measures regarding copy number
aberration detection
dataset method sum 0-1 err SSQ SSQ n /
( K  01, T  BinErrAk ) 51.53 86.08 0.19
A ( K  01, T  Joint ) 146.91 596.78 0.49
( K Peaks Peaks   ,, ,, , 005 005 005 005 T ) 91.99 345.64 0.37
( K  01, T  BinErrAk ) 421.79 1226.59 0.70
( K Peaks Peaks   ,, ,, , 005 005 005 005 T ) 110.39 287.21 0.34
( K Peaks Peaks   ,, ,, , 01 01 01 01 T ) 109.39 286.15 0.34
B ( KT Peaks Peaks   ,_,_ ,_,_ , 01 90 01 90 01 90 01 90 ) 141.65 370.78 0.38
( KT Peaks mad mad Peaks mad mad   ,, ,, , ) 154.56 424.2 0.41
( K Peaks mad Peaks mad   ,, ,, , 01 01 T ) 109.39 286.15 0.34
( K Peaks mad Peaks mad   ,, ,, , 01 01 T ) 111.75 283.77 0.34
The table shows some error measures regarding the copy number event estimation obtained with several methods on datasets A and B. While ( K  01, T  BinErrAk )
outperforms the other methods on dataset A,o nB it obtains a poor estimation of the copy number events in comparison with the other methods. On dataset B,
the methods which achieve the lowest errors are: ( K Peaks Peaks   ,, ,, , 01 01 01 01 T ), ( K Peaks Peaks   ,, ,, , 005 005 005 005 T ), ( K Peaks mad Peaks mad   ,, ,, , 01 01 T )a n d(K Peaks mad Peaks mad   ,, ,, , 01 01 T ).
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Page 12 of 18data are plotted in Supplementary Figure S.8 in Addi-
tional file 2). Regarding the copy-neutral LOH estima-
tion, all methods (apart from PennCNV) were able to
identify the aberrations, but sometimes dChip divided
the biggest lesions into small regions of aberration (e.g.
the plot at the bottom right-hand side of Figure 6).
Instead, only gBPCR and CNAT were usually able to
detect LOH regions due to deletions. In this case,
CNAT divided the biggest aberrations in small regions
of LOH, losing part of the lesions. In Figure 6, we can
also appreciate the differences in the estimation of the
regions of gain between gBPCR and PennCNV. In both
examples with regions of loss (the plots at the top and
at the bottom left-hand side), the segments outside the
losses represent gains. gBPCR failed to identify only one
of these lesions, instead PennCNV did not recognize
almost any of them (for thoroughness, we plotted also
the copy number events, estimated by the HMM meth-
ods implemented in dChip and CNAT, in Supplemen-
tary Figure S.9 in Additional file 2). In the next section,
by applying gBPCR to a real dataset from [23], we will
be able to discuss its performance in the identification
of genomic gains, depending on the copy number of the
alleles (e.g. CN = 4 and both alleles have CN = 2 or one
allele has CN = 1 and the other CN = 3).
Finally, we also evaluated the effect of the adjustment
of the model parameters related to the NoCall detection
(see Section “Methods”), using the same data. At low or
medium noise, no significant differences in the goodness
of the estimation could be observed (see, for example,
Supplementary Figure S.10 in Additional file 2). Instead,
in presence of high noise, the FPR regarding the IBD/
Figure 6 Examples of profile estimation. The plot shows four examples of chromosomic profile estimation in samples with SNR = 1.25 (high
noise). The version of gBPCR employed was the one which uses ( K Peaks Peaks   ,, ,, , 01 01 01 01 T ) and pupd =1 0
-4. As notations: 1 corresponds to
gain, 0 to normal status, -1 to loss. IBD/UPD regions and unspecified LOH regions are depicted with values close to zero. All methods (apart
PennCNV) are able to identify the copy-neutral LOH regions, but sometimes dChip divides the biggest lesions in small ones. Only gBPCR and
CNAT are able to detect LOH regions due to deletions and in this case CNAT divides the biggest aberrations into small regions of LOH.
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parameters was close to one. In fact, in this situation a
segment with normal copy number is more often classi-
fied as IBD/UPD, since the NoCall rate is higher and,
without the correction, the IBD/UPD segments are
allowed to contain a higher percentage of NoCallsw i t h
respect to the normal ones. Instead, with the adjust-
ment, all types of regions are allowed to have a higher
number of NoCalls in proportion to the noise, obtaining
a less biased estimation.
In conclusion, we suggest to use ( K Peaks Peaks   ,, ,, , 01 01 01 01 T )
or ( K Peaks mad Peaks mad   ,, ,, , 01 01 T )w i t hpupd =1 0
-4, due to their
good results obtained on the non-informative SNPs. A
detailed description of all the results is in Section S.6 in
Additional file 2.
Application to real data
In this subsection, we show the behavior of gBPCR on
three real datasets. The first dataset consisted of eight
paired cancer samples of patients affected by chronic
lymphocytic leukemia (CLL), which then developed in
diffuse large B-cell lymphoma (DLBCL), see [37,38]. For
two patients we had also a third sample, thus the total
number of samples was 18. The second dataset con-
sisted of 18 patients affected by CLL, see [39]. For both
of these datasets, genome-wide DNA profiles were
obtained using the GeneChip Human Mapping 250K
NspI (Affymetrix, Santa Clara, CA, USA). The genotype
calls were calculated with BRLMM [26] using 46 Cauca-
sian normal female samples of the HapMap Project as
reference samples and the raw copy number data were
retrieved using CNAT 4.01 [36]. In [37-39], the copy
number of some genomic regions was also measured
with fluorescent in situ hybridization (FISH). Therefore,
on these regions we compared the copy number event
estimated by gBPCR with the copy number measured by
FISH. Moreover, since samples coming from the same
patient should present the same copy-neutral LOH
regions (the germ line ones) for the majority of the gen-
ome, we used the two patients with three samples to
evaluate the IBD/UPD detection of gBPCR.
The third dataset was a dilution series of the CRL-
2324 breast cancer cell line from [23]. The series com-
prised 12 samples, corresponding to the following per-
centages of tumor content: 0, 10, 14, 21, 23, 30, 34, 45,
47, 50, 79, 100. The genome-wide DNA profiles were
obtained using Illumina 370K BeadChips. The authors
preprocessed the data with BeadStudio software (Illu-
mina Inc.) and we used both the genotyping and logRra-
tio data available at [40]. In [23], the authors chose eight
genomic aberrations and compared the estimation given
by their method (called BAFsegmentation) with the ones
of the following algorithms: dChip [16], PennCNV [24],
QuantiSNP [20] and SOMATICs [18]. Thus, we
compared the estimations of these genomic regions
given by gBPCR with the ones given by the previous
methods. We also used these data to evaluate the per-
formance of gBPCR in the detection of gains, for differ-
ent values of the allelic copy numbers.
Based on the previous results on simulated data, for
the analysis of these real data, we used:
( K Peaks Peaks   ,, ,, , 01 01 01 01 T ), as paired estimators of the
number of segments and the boundaries, and pupd =
10
-4 as prior probability of IBD/UPD.
Results regarding the identification of the copy number
changes in CLL samples
We recall that an individual cancer sample can repre-
sent a mixture of neoplastic and normal cells. Moreover,
the tumor cells themselves do not represent a geneti-
cally homogeneous population, since individual genetic
lesion might be present in only a fraction of the cells. In
fact, Figure 7 shows that the log2ratio values corre-
sponding to normal, gain, loss regions are sufficiently
well separated only when the copy number changes are
borne in at least 60% of the cells of the DNA sample.
As a consequence, we aim to detect the copy number
changes borne in at least the 60% of the cells, otherwise
we cannot ensure that the identified aberrations are true
and not due to the noise of the microarray data (the
noise is so high that aberrations borne in only a small
percentage of cells can be seen as noise and viceversa).
To detect aberrations in even less cell content, it is
Figure 7 Example of copy number event classification. The plot
shows the estimated log2ratio values (given by mBPCR), as function
of the estimated percentage of cells bearing the aberration (given
by FISH). The aberrations considered in the graph were identified by
FISH on 18 patients of [37,38], for a total of 133 interrogated
genomic regions. The copy number changes are classified as loss,
gain or normal, using the results given by the FISH. For the normal
regions, we set the percentage as 100%. The estimated log2ratio is
the one of the genomic region interrogated by FISH. We can
observe that only the aberrations borne in at least 60% of the cells
are clearly separated.
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to zero. In practice, the prior of Z influences more the
discovery of the gains than the one of the other copy
number events, because the determination of gains
depends mainly on the estimated log2 ratio values
(rather than the LOH data).
In the samples considered for the comparison, we had a
total of 169 regions measured by FISH (which provides
also an estimate of the percentage of cells bearing the
aberration): 38 regions were gains or losses in at least 60%
of the cells (called detectable aberrations), 33 were gains
or losses in less than 60% (called less detectable aberra-
tions) and 98 were identified as normal segments. Regard-
ing the detectable aberrations, only two copy number
events were not identified by our algorithm. One loss was
not found, because the estimated log2ratio was very close
to zero, and the other, because of a different percentage of
Het SNPs from what was expected by our algorithm. We
discovered 13 of the 33 less detectable copy number
changes and we also detected two of the 98 normal seg-
ments as aberrations, but one of these copy number
changes was equal to the one discovered in the same
region of the paired sample, thus it was likely to be true.
Instead, by simply using the thresholds of the prior of
Z on the profiles estimated by mBPCR for the classifica-
tion of the copy number events (similarly to what is
usually done), we detected one alteration less than what
found by gBPCR and other 5 normal regions were seen
as aberrations.
For the analysis of the results, we have to consider
that the samples used for FISH came from peripheral
blood, for the CLL samples, and from paraffn embedded
tissues or lymph node, for the DLBCLs. Because of the
consequently different cell content, in the former case,
the results are better estimated. Moreover, the samples
used for microarray and FISH might not be exactly the
same, hence the percentage of cells which carry the
aberrations can be different and a discordance between
the two techniques is possible. Thus, gBPCR performed
well in estimating the copy number changes on these
samples.
Results regarding IBD/UPD region detection in CLL samples
For the evaluation of the IBD/UPD region detection, we
considered the two patients with three samples. For the
first patient (called Patient 1), we had: one matched nor-
mal DNA sample extracted from peripheral blood gran-
ulocytes (called Sample 1.1), one sample from neoplastic
cells at CLL phase (called Sample 1.2) and the last one
from neoplastic cells at DLBCL phase (called Sample
1.3). For the second patient (Patient 2), we had: one
sample from neoplastic cells at CLL phase (called Sam-
ple 2.1), one at DLBCL phase (called Sample 2.2) and
the last one from neoplastic cells at a further progres-
sion of the DLBCL (called Sample 2.3).
Applying gBPCR to the three samples of Patient 1, we
found that the number of aberrations in each sample
increased with the progression of the disease. The lower
number of segments discovered in Sample 1.1 could
also be due to a higher NoCall rate in comparison to
the other samples. The same happened for Sample 2.3
of Patient 2.
We compared the IBD/UPD segments found in the
three samples of each patient and we divided them into
three classes (see Supplementary Table S.6 in Additional
file 2):
￿ equal regions: segments that are exactly the same
in two or three samples;
￿ overlapping regions: segments that are common in
at least two samples but do not have the same
boundaries;
￿ single sample regions: the remaining segments.
Then, we defined the number of distinct regions as
the sum of all these regions and the number of validated
ones as the sum of all types of regions except the single
sample regions. The proportions of equal and overlap-
ping regions were similar in the two patients and the
validated regions were 73% of the distinct regions
detected in Patient 1 and 79% of the distinct regions in
Patient 2. The single sample regions were about the 21%
of the distinct regions in Patient 2, but the majority of
them had length less than 50 SNPs. Instead, since the
samples of Patient 1 belonged to different stages of the
disease, in this patient we found a higher number of sin-
gle sample regions and most of them were wider than
50 SNPs. In fact, the majority of these regions was
detected in Sample 1.3, thus they were likely to be
somatic.
Results regarding the identification of genomic aberrations
in the dilution series
In [23], the authors observed that the BeadStudio nor-
malization produced copy number profiles which were
centered differently as the tumor content decreased and,
as a consequence, many algorithms wrongly assigned
the type of genetic aberration. Therefore, they evaluated
the methods by considering only if they found any aber-
ration in the eight regions considered, without looking
at the type of aberration.
Due to this variation in centering the normal copy
number, we estimated the histogram of the estimated
log2ratio values (which is used for the definition of the
prior of Z), separately by using only samples with simi-
lar tumor content. Nevertheless, this shrewdness was
not suffcient to well distinguish the peaks of the histo-
gram in some cases.
For all samples, we computed the sensitivity in detect-
ing the eight aberrations considered in [23]. For each of
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ing if gBPCR found any aberration (like in [23]) and by
looking if it found the correct lesion (see Supplementary
Figures S.11 and S.12 in Additional file 2). By comparing
the results obtained by gBPCR using the first type of
sensitivity with the ones given by the other methods in
Figure 7 of [23], we can observe that gBPCR outper-
formed dChip and PennCNV and often also QuantiSNP.
Sometimes it also performed better than BAFsegmenta-
tion and SOMATICs in the detection of the regions of
gain. Moreover, occasionally gBPCR had a non-zero sen-
sitivity in the normal sample, because it detected small
IBD/UPD regions. By looking at the results obtained by
gBPCR with the second type of sensitivity, we can notice
that the correct aberration was usually detected in sam-
ples with at least 60% of tumor content and the sensitiv-
ity was still often higher than the one of dChip and
PennCNV.
Finally, we computed the sensitivity of gBPCR for
eight regions of gain, to evaluate its performance
depending on the value of the copy number of the
alleles. For all eight lesions, the total copy number was
f o u r .I n s t e a d ,t h em i n o ra l l e l ec o p yn u m b e r( maCN ,i .
e. the copy number of the allele less frequent in a nor-
mal population) changed from two to zero. The selec-
tion of these regions of gain was based on the
estimated genomic profile of CRL-2324, provided by
The Cancer Genome Project at the Wellcome Trust
Sanger Institute and available at [41]. For each aberra-
tion, the sensitivity was computed in two ways: by
looking if the region was identified as a gain and by
looking if it was detected as either a gain or an IBD/
UPD segment (see Supplementary Figure S.13 in Addi-
tional file 2).
The differences between the two types of sensitivity
were observed for some percentages of tumor content, in
gains with maCN =2o rmaCN = 0. Regarding the
lesions with maCN = 2, a small part of the gain was iden-
tified as IBD/UPD region in few cases with a small per-
centage of tumor content. This phenomenon was due to
the presence of a high percentage of homozygous SNPs
with copy number close to the normal copy number. For
the same reason, the whole gain 6q22.31 (maCN = 0) was
identified as an IBD/UPD region at 100% and 79% per-
centages of tumor content and the same happened also
for a part of 6q15 (maCN =0 )a t7 9 % .A sw ee x p l a i n e d
in Section “Method”, the detection of the gains highly
depends on the copy number value. Thus, if the copy
number of a region of gain is close to the normal value, it
is identified as either normal or IBD/UPD, depending on
the homozygous status of the SNPs inside it. Therefore,
the performance of gBPCR depends mainly on the quality
of the copy number data and not on the value of the copy
number of the alleles.
Conclusions
We have derived a new algorithm (called gBPCR) for
the simultaneous estimation of copy number changes
and IBD/UPD regions, by using both copy number and
genotyping data. To the best of our knowledge, only one
other algorithm exists which uses the same input data
for the same purpose [17], but it does not appear appro-
priate for data coming from a DNA sample of a mixture
of cell populations (like cancer DNA samples).
Our model takes into account the errors due to both the
microarray procedure and the biological processes that lead
to aberrations affecting the DNA copy number and the
homozygous status. Because of the complexity of the algo-
rithm and the high noise of the real data, we introduced
new estimators to improve the detection of the breakpoints.
On the basis of the results on simulated data, we selected
the best performing one: ( K Peaks Peaks   ,, ,, , 01 01 01 01 T ).
On the artificial dataset of [35] (and especially in sam-
ples with high noise), gBPCR outperformed three well-
known methods which estimate regions of LOH: dChip
[16], CNAT [36] and PennCNV [24]. We also tested
gBPCR on real data. On 36 CLL samples [37-39], we
found a high agreement between the copy number
changes estimated by gBPCR and the ones obtained by
FISH (used as reference). Moreover, on two patients
with three samples we could validate at least 73% of the
identified IBD/UPD segments. On the samples of the
CRL-2324 dilution series of [23], we showed that in
samples with at least 60% of tumor content, gBPCR was
able to detect the genomic aberrations, while with less
tumor content only some aberrations could be seen.
Moreover, on these data gBPCR outperformed dChip
[16] and PennCNV [24] and sometimes QuantiSNP
[20]. Since other methods (SOMATICs [18] and BAF-
segmentation [23]), which use the allelic copy number
information, seemed to perform well, as future work we
intend to add also this useful information in our model.
Availability and requirements
Project name: gBPCR.
Project home page: http://www.idsia.ch/~paola/
gBPCR/.
Operating systems: the software should run in Linux,
Mac-OS or Windows. Tests were performed on Win-
dows and Linux systems.
Programming language:R .
Other requirements: none.
Licence: GNU GPL.
Any restrictions to use by non-academics: none.
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Additional file 1: gBPCR source code. This zipped file contains the
source code of the gBPCR algorithm in R, including help files, sample
data and examples.
Additional file 2: Supplementary material. This file contains: 1) the
description of the estimation of the parameters of the likelihood, 2) the
explanation of the estimation of density of the estimated log2ratio levels,
3) explicit formulae of some quantities employed in the dynamic
programming used to implement our method, 4) the explanation of an
algorithm for the determination of the maxima of a multimodal function,
5) detailed description of the results obtained on simulated data, 6)
some supplementary tables and 7) some supplementary figures.
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